<DOC>
	<DOC>NCT00243503</DOC>
	<brief_summary>The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of tumor control and survival; assess patient reported outcomes; assess PK in combination with trastuzumab and compare efficacy and safety.</brief_summary>
	<brief_title>Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>A diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or 2) metastatic disease. HER2 positive disease (3+ by immunohistochemistry [IHC] or FISHpositive) Candidate for treatment with trastuzumab. Prior treatment with trastuzumab and or/ lapatinib in the neoadjuvant, adjuvant or metastatic disease setting is permitted. Treatment with hormone therapy in the adjuvant and/or advanced disease setting is permitted. Prior treatment with &gt;1 regimen of cytotoxic therapy in the advanced disease setting. Adjuvant chemotherapy is permitted Prior exposure to trastuzumab if the patient had developed severe hypersensitivity reactions. Prior treatment on a SU11248 clinical trial. Uncontrolled brain metastases.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Breast Cancer Metastatic</keyword>
</DOC>